



ESMO Preceptorship on Prostate Cancer

PROGRAMME

**ESMO
PRECEPTORSHIP**

**LUGANO SWITZERLAND
18-19 DECEMBER 2024**

Co-Chairs

Karim Fizazi, France

Silke Gillissen, Switzerland

ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
18-19 December 2024

CO-CHAIRS Karim Fizazi, France
Silke Gillessen, Switzerland

SPEAKERS Giulia Baciarello, Italy
Elena Castro, Spain
Eva Compérat, Austria
Ken Herrmann, Germany
Jochen Walz, France
Thomas Zilli, Switzerland

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

Johnson & Johnson

Supported by a grant from Pfizer Inc.

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Wednesday, 18 December 2024

09:00-09:10 10'	Opening and welcome	
10'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR Silke Gilllesen, CH
09:10-10:50 100'	SESSION 1 Screening, diagnosis, staging and localised prostate cancer	Chairs: Eva Compérat, AT Jochen Walz, FR
15'	PSA screening and diagnosis	Jochen Walz, FR
10'	Staging	Jochen Walz, FR
15'	Pathological diagnosis for the clinician (including variants of PCa)	Eva Compérat, AT
15'	Treatment of localised prostate cancer according to risk category	Jochen Walz, FR
15'	Radiotherapeutic approaches for localised prostate cancer	Thomas Zilli, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
10:50-11:20	Coffee break	
11:20-12:45 85'	SESSION 2 Biochemical relapse	Chairs: Giulia Baciarello, IT Thomas Zilli, CH
15'	Biochemical relapse: Definition and diagnostic algorithm	Giulia Baciarello, IT
20'	Rising PSA after radical local treatment: Prognosis, indications for salvage local treatments, salvage vs adjuvant treatments	Thomas Zilli, CH
20'	Use of early vs deferred systemic treatments in high-risk localized CaP and biochemical failures	Karim Fizazi, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
12:45-13:45	Lunch	
13:45-15:25 100'	SESSION 3 Systemic treatment options and molecular characterisation	Chairs: Elena Castro, ES Jochen Walz, FR
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gilllesen, CH
20'	Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Elena Castro, ES
15'	Bone health agents, mechanism of action, efficacy and toxicities	Giulia Baciarello, IT
15'	Molecular characterisation: Germline and somatic testing	Elena Castro, ES
15'	Q&A	All

15'	Participants clinical case discussion (1x15')	Faculty
15:25-15:55	Coffee break	
15:55-17:25 90'	SESSION 4 Castration-sensitive metastatic prostate cancer	Chairs: Karim Fizazi, FR Silke Gillessen, CH
20'	Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Silke Gillessen, CH
15'	Triplet and quadruplet options (mCSPC)	Karim Fizazi, FR
10'	Monitoring of mCSPC	Ken Herrmann, DE
15'	Oligo-metastatic disease: What treatment?	Thomas Zilli, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
19:30	Networking Dinner	

Thursday, 19 December 2024

09:00-10:45 105'	SESSION 5 Non metastatic and metastatic castration-resistant disease	Chairs: Giulia Baciarello, IT Elena Castro, ES
20'	Non metastatic CRPC: Current treatment	Giulia Baciarello, IT
20'	Metastatic CRPC: Current treatment	Silke Gillessen, CH
20'	PSMA-based therapies	Ken Herrmann, DE
15'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
10:45-11:15	Coffee break	
11:15-12:20 65'	SESSION 6 Metastatic castration-resistant disease	Chairs: Karim Fizazi, FR Silke Gillessen, CH
15'	Treatment in frail patients with mCRPC	Elena Castro, ES
20'	Experimental treatments for mCRPC	Karim Fizazi, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
12:20-12:30 10'	Conclusion and farewell	Karim Fizazi, FR Silke Gillessen, CH
12:30-13:30	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion